Opinion
Video
Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC
Panelists discuss how, if the MARIPOSA trial shows an overall survival advantage exceeding 1 year, the amivantamab-lazertinib combination may see increased frontline use. Subsequent therapy options could include chemotherapy, targeted therapies based on resistance mechanisms, or clinical trials for emerging treatments.
Video content above is prompted by the following:
If the MARIPOSA overall survival data exceeds a 1-year advantage as is projected, do you anticipate seeing the amivantamab with lazertinib combination used more frequently in the frontline setting? If so, what treatment options are available for subsequent therapy?
Latest CME
View All
Video
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
May 14th 2025 - May 15th 2026
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
May 13th 2025 - Jun 18th 2025
online-activity
Video
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
May 9th 2025 - Jun 14th 2025
online-activity
Related Content
.jpg?fit=crop&auto=format)
